Eli Lilly and Co (TSX:LLY) 3-Year Sortino Ratio: N/A (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:LLY Eli Lilly and Co TSX:LLY
85 GF Score
Price C$41.12
GF Value C$55.89
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co 3-Year Sortino Ratio?

The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2026-09-21), Eli Lilly and Co's 3-Year Sortino Ratio is Not available.


Eli Lilly and Co  (TSX:LLY) 3-Year Sortino Ratio Explanation

The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Eli Lilly and Co 3-Year Sortino Ratio Related Terms


TSX:LLY vs JNJ, ABBV, MRK: 3-Year Sortino Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co 3-Year Sortino Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's 3-Year Sortino Ratio falls into.


TSX:LLY
85GF Score
Eli Lilly and Co TSX:LLY
3-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co 3-Year Sortino Ratio Calculation

The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Eli Lilly and Co (TSX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of C$41.12 is trading 26.4% below its estimated GF Value™ of C$55.89. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for TSX:LLY:

  • 3-Year Sortino Ratio: N/A
  • GF Value™: C$55.89 vs. price of C$41.12 (26.4% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the TSX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
85GF Score

Get the complete analysis for TSX:LLY

3-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$41.12
Price
C$55.89
GF Value